Early detection drives a dramatic survival gap for colorectal cancer. A 5-year survival rate rises from 14% for advanced disease to 90% for localized cases. These statistics trace how diagnosis stage, lifestyle factors, and care access shape survivorship outcomes long after treatment ends.
Key Takeaways
- Early detection increases colorectal cancer 5-year survival from 14% advanced to 90% localized.
- 65% of US cancer survivors receive survivorship care plans.
- Secondhand smoke exposure worsens respiratory QoL in lung survivors.
- 42% of survivors report chronic pain impacting quality of life and adherence.
- In the United States, approximately 18.1 million people were living with a history of cancer as of January 2022: June 2026, representing cancer survivors.
Cancer survivorship is growing, and more people than ever are living longer after diagnosis.
Related reading
01 · Category
Factors Influencing Survivorship25 stats
01
Early detection increases colorectal cancer 5-year survival from 14% advanced to 90% localized.
02
Obesity raises risk of cancer recurrence by 1.3-3.4 times in survivors per meta-analysis.
03
Smoking after lung cancer diagnosis reduces 5-year survival by 30-50% compared to quitters.
04
Physical activity post-diagnosis lowers breast cancer mortality by 34% for most active survivors.
05
Diabetes in cancer survivors increases mortality risk by 20-50% depending on cancer type.
06
Socioeconomic status low correlates with 20% lower survival rates across cancers in US.
07
Access to high-volume hospitals improves pancreatic cancer survival by 25%.
08
Genetic testing identifies 10-15% BRCA mutations in breast cancer survivors aiding family screening.
09
Immunotherapy response rates in melanoma survivors reach 50% for advanced cases with PD-1 inhibitors.
10
Adherence to endocrine therapy in breast cancer survivors >80% adherence yields 50% mortality reduction.
11
Younger age (<50) at colorectal cancer diagnosis associates with 15% higher recurrence risk.
12
Rural residence decreases cancer survival by 10-20% due to delayed care per CDC data.
13
Hispanic cancer survivors have 10% lower survival rates than non-Hispanic whites adjusted for stage.
14
Comorbid heart disease increases breast cancer mortality by 1.5-fold in survivors over 65.
15
HPV vaccination reduces cervical cancer precursor lesions by 90% in young women.
16
Mediterranean diet adherence in survivors cuts all-cause mortality by 28%.
17
Chronic inflammation markers high in 40% survivors predict poorer outcomes.
18
Telemedicine follow-up improves adherence by 25% in rural survivors.
19
75% of survivors with depression experience worse survival; treatment improves by 20%.
20
Alcohol consumption >1 drink/day post-diagnosis raises breast cancer recurrence 15%.
21
High BMI (>30) at diagnosis increases endometrial cancer recurrence 2-fold.
22
Multidisciplinary care teams boost survival 15% in head/neck cancer.
23
Sleep >7 hours/night post-treatment lowers mortality 19% in survivors.
24
Financial toxicity affects 50% survivors, linking to 2x treatment non-adherence.
25
Exercise 150 min/week reduces fatigue 40% and improves survival odds.
Interpretation
Factors Influencing Survivorship Interpretation
Cancer survivorship statistics reveal a surprisingly clear and often galling formula: your odds of beating cancer are dramatically stacked by the mundane—catching it early, staying active, eating well, quitting smoking, and having money and a good address—while they are cruelly undermined by its equally mundane opposites: poverty, poor access, and unhealthy habits.
02 · Category
Healthcare and Support Systems26 stats
01
65% of US cancer survivors receive survivorship care plans.
02
Only 48% survivors followed up by oncology >1 year post-treatment.
03
Survivorship clinics serve <10% of eligible survivors nationally.
04
Medicare covers screening for secondary cancers in 80% survivors.
05
Nurse navigators improve follow-up adherence by 25%.
06
Palliative care integration boosts QoL in 70% advanced survivors.
07
Telehealth visits rose 400% for survivors during COVID-19.
08
Support groups participation 30% among survivors, reducing isolation.
09
Annual wellness visits detect comorbidities in 60% survivors.
10
Genetic counseling uptake 20% in high-risk survivors.
11
Rehab services utilized by 15% for physical late effects.
12
Insurance loss affects 5% survivors post-treatment.
13
Digital health apps used by 40% for symptom tracking.
14
Primary care coordination lacking in 55% survivors.
15
Vaccine uptake for flu 70%, COVID 60% among survivors.
16
Peer mentoring programs reach 10% improving coping skills.
17
Cost of survivorship care averages $4000/year per patient.
18
Rural survivors travel 50+ miles average for follow-up.
19
Psychosocial services accessed by 25% with distress.
20
Bone density screening in 50% at-risk survivors.
21
Transition to primary care smooth for 40% survivors.
22
Financial assistance programs aid 20% with out-of-pocket costs.
23
Survivorship research funding $200M annually from NCI.
24
85% survivors desire personalized care plans.
25
Cardiac screening guidelines followed in 60% high-risk.
26
Exercise programs prescribed to 30% for QoL improvement.
Interpretation
Healthcare and Support Systems Interpretation
Cancer survivorship in America is a patchwork of promising progress and perilous gaps, where high-tech solutions and dedicated nurses make a tangible difference, yet too many survivors still fall through the cracks of a fragmented system that knows what to do but often fails to deliver it consistently.
03 · Category
Late Effects and Complications23 stats
01
Secondhand smoke exposure worsens respiratory QoL in lung survivors.
02
Cardiovascular disease risk doubles in Hodgkin lymphoma survivors 30 years post-treatment.
03
Secondary cancers occur in 10-15% childhood cancer survivors by age 50.
04
Osteoporosis fractures 5x higher in breast cancer survivors on aromatase inhibitors.
05
Pulmonary toxicity in 20% survivors post-bleomycin for testicular cancer.
06
Thyroid dysfunction in 50% Hodgkin survivors post-radiation.
07
Infertility permanent in 30% male survivors post-chemotherapy.
08
Hearing loss in 20-30% survivors treated with platinum drugs.
09
Cardiac events 7x higher in childhood cancer survivors per CCSS study.
10
Recurrence rate 20-30% in melanoma survivors within 5 years.
11
Avascular necrosis in 5-10% pediatric survivors post-steroids.
12
Chronic kidney disease in 20% survivors post-cisplatin.
13
Dry mouth xerostomia permanent in 40% post-head/neck radiation.
14
Peripheral artery disease risk 2.5x in testicular cancer survivors.
15
Breast cancer recurrence 10% risk at 10 years for stage I post-lumpectomy.
16
Metabolic syndrome in 40% lymphoma survivors 10 years post.
17
Cataracts 5x higher in survivors post-cranial radiation.
18
Colorectal cancer local recurrence 10-15% post-surgery.
19
Hypothyroidism 20-30% in breast cancer survivors post-radiation.
20
Skin cancers 5x increased in non-melanoma survivors post-radiation.
21
15% survivors develop new primary cancers within 10 years.
22
Neurologic deficits persist in 25% brain tumor survivors.
23
35% of long-term survivors experience treatment-related pain.
Interpretation
Late Effects and Complications Interpretation
To survive cancer is often to trade one set of shadows for another, a lifelong vigil where the echoes of treatment can manifest as new and varied threats to the body.
More related reading
04 · Category
Quality of Life Post-Treatment25 stats
01
42% of survivors report chronic pain impacting quality of life and adherence.
02
Breast cancer survivors experience sexual dysfunction in 60-100% cases post-treatment.
03
30% colorectal survivors have persistent bowel dysfunction 5 years post-surgery.
04
Fatigue persists in 33% cancer survivors beyond 10 years post-diagnosis.
05
Cognitive impairment "chemo brain" affects 75% during treatment, 35% at 20 years.
06
25% survivors report moderate-severe anxiety 1 year post-treatment.
07
Lymphedema occurs in 20% breast cancer survivors, severely impacting arm function.
08
17% survivors unemployed 1 year post-diagnosis due to health issues.
09
Sleep disturbances in 50-70% survivors, linked to poorer QoL scores.
10
Body image dissatisfaction in 40% female survivors post-mastectomy.
11
Neuropathy persists in 40% post-chemotherapy at 6 months, 30% at 2 years.
12
28% prostate cancer survivors report urinary incontinence 2 years post-treatment.
13
Fear of cancer recurrence highest at 65% in first year, 40% at 5 years.
14
Financial distress reported by 49% survivors, correlating with lower QoL.
15
Social isolation affects 20% survivors, worsening depression scores.
16
Hot flashes in 70% breast cancer survivors on tamoxifen, impacting sleep.
17
35% survivors have osteoporosis risk post-treatment due to hormones/chemo.
18
Return to work rate 64% at 1 year for working-age survivors.
19
Fertility concerns distress 76% young female survivors pre-treatment.
20
Oral health issues in 40% head/neck survivors post-radiation.
21
Weight gain average 5-10kg in 60% breast survivors post-diagnosis.
22
Partner relationship strain in 25% couples post-cancer diagnosis.
23
Mindfulness programs improve QoL scores by 15-20% in survivors.
24
22% survivors report chronic diarrhea 5+ years post-radiation for pelvic cancers.
25
Erectile dysfunction in 60-80% prostate survivors post-surgery/radiation.
Interpretation
Quality of Life Post-Treatment Interpretation
Cancer leaves a long and often invisible receipt, with the physical, emotional, and financial costs continuing to mount long after the initial shock of diagnosis has faded.
05 · Category
Survival Rates by Cancer Type29 stats
01
In the United States, approximately 18.1 million people were living with a history of cancer as of January 2022: June 2026, representing cancer survivors.
02
The 5-year relative survival rate for all cancers combined improved from 49% in the mid-1970s to 68.7% during 2014-2020 in the US.
03
For breast cancer in females, the 5-year relative survival rate is 91.1% for localized disease, 86.4% for regional, and 31.9% for distant metastatic stages based on 2014-2020 SEER data.
04
Prostate cancer has a 5-year relative survival rate of nearly 100% for localized and regional stages, and 32.4% for distant stage from 2014-2020 data.
05
Lung and bronchus cancer 5-year survival rate is 26.7% overall, but only 7.1% for distant stage cases diagnosed 2014-2020.
06
Colorectal cancer 5-year relative survival is 91.0% localized, 72.1% regional, 16.6% distant per SEER 2014-2020.
07
Melanoma of the skin has a 5-year survival of 99.6% localized, 68.8% regional, 30.8% distant from recent SEER data.
08
For thyroid cancer, 5-year survival exceeds 99% for localized, 98% regional, 55% distant stages 2014-2020.
09
Bladder cancer 5-year survival: 96.5% localized, 71.0% regional, 6.4% distant per SEER.
10
Non-Hodgkin lymphoma 5-year survival is 74.2% overall, 84.0% localized, 39.1% distant 2014-2020.
11
Kidney and renal pelvis cancer: 92.9% localized, 72.3% regional, 15.6% distant 5-year survival.
12
Uterine corpus cancer 5-year survival: 95.3% localized, 70.3% regional, 19.0% distant.
13
Leukemia overall 5-year survival 65.7%, with acute lymphocytic leukemia at 71.7% for 2014-2020.
14
Pancreatic cancer has one of the lowest 5-year survivals at 12.5% overall, 44.3% localized.
15
Liver and intrahepatic bile duct cancer: 21.2% overall, 37.0% localized 5-year survival.
16
Oral cavity and pharynx cancer 5-year survival: 86.6% localized, 24.0% distant.
17
Esophageal cancer 5-year survival 21.0% overall, 48.7% localized.
18
Stomach cancer: 36.2% overall, 75.4% localized 5-year survival 2014-2020.
19
Brain and other nervous system cancer 5-year survival 36.0%, 36.8% localized.
20
Multiple myeloma 5-year survival 59.8% overall, 78.6% localized.
21
Black women with breast cancer have a 5-year survival rate of 82.7% compared to 92.2% for White women per recent ACS data.
22
Childhood cancer 5-year survival has risen to 86% for diagnoses 2014-2020 from SEER pediatric data.
23
Testicular cancer 5-year survival 95.3% overall, nearly 100% for seminoma localized.
24
Cervical cancer 5-year survival 66.0% overall, 92.9% localized.
25
Ovarian cancer 5-year survival 49.1% overall, 93.1% localized stage.
26
Hodgkin lymphoma 5-year survival 89.4% overall.
27
In Europe, 5-year survival for breast cancer averages 87.3% varying by country per CONCORD-3 study.
28
UK breast cancer 10-year net survival is 78% for women diagnosed 2010-2011.
29
Australia prostate cancer 5-year survival 95% for 2015-2019 diagnoses.
Interpretation
Survival Rates by Cancer Type Interpretation
The numbers tell a story of remarkable progress, yet they also serve as a stark reminder that our battle against cancer remains a race against the clock, where early detection is still our most powerful weapon and late-stage disease a formidable enemy.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Sutherland. (2026, February 13). Cancer Survivorship Statistics. Gitnux. https://gitnux.org/cancer-survivorship-statistics
MLA
David Sutherland. "Cancer Survivorship Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cancer-survivorship-statistics.
Chicago
David Sutherland. 2026. "Cancer Survivorship Statistics." Gitnux. https://gitnux.org/cancer-survivorship-statistics.
Sources & references
13 datasets cited across this report · attribution is report-level